10 Oversold Global Stocks To Buy
In this piece, we will take a look at ten oversold global stocks to buy. If you want to skip our analysis of the global economic climate, then take a look at 5 Oversold Global Stocks To Buy. Like Jul...
- Supported exchanges /
- NASDAQ /
- GLMD.NASDAQ
Galmed Pharmaceuticals Ltd (GLMD NASDAQ) stock market data APIs
$3.6795
0.22(6.4%)
as of October 17, 2024
Price chart is built with Anychart
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Galmed Pharmaceuticals Ltd Financial Data Overview
| 3.46 | |
| 3.6795 | |
| - | |
| 3.68 | |
| 3.4 | |
| 2.73-15.1 | |
| 5 485 K | |
| 1 507 K | |
| 0 | |
| -2.1332 | |
| 0.73 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'GLMD',
Type:
'Common Stock',
Name:
'Galmed Pharmaceuticals Ltd',
Exchange:
'NASDAQ',
CurrencyCode:
'USD',
CurrencyName:
'US Dollar',
CurrencySymbol:
'$',
CountryName:
'USA',
CountryISO:
'US',
OpenFigi:
'BBG005ZD02W1',
ISIN:
'IL0011313900',
CUSIP:
'M47238106',
CIK:
NULL,
EmployerIdNumber:
'98-1147233',
FiscalYearEnd:
'December',
IPODate:
'2014-03-13',
InternationalDomestic:
'Domestic',
Sector:
'Healthcare',
Industry:
'Biotechnology',
HomeCategory:
'ADR',
IsDelisted:
false,
}
Galmed Pharmaceuticals Ltd Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -6 145 000
- Earnings Per Share -9.69
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Galmed Pharmaceuticals Ltd Earnings via APIs
- Latest Release 2024-08-23
- EPS/Forecast NaN
Get Galmed Pharmaceuticals Ltd End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Galmed Pharmaceuticals Ltd latest news via APIs
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada
Endo International plc’s ENDP wholly owned subsidiary, Endo Ventures Limited, has entered into an agreement with Quoin Pharmaceuticals Inc. QNRX for the development, supply, commercialization and di...
- ENDO INTERNATIONAL
- GALMED PHARMACEUTICALS
- NETHERTON SYNDROME
- ZACKS INVESTMENT RESEARCH
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
